6 Comparative analysis of the pathogenicity between multidrug-resistant Acinetobacter baumannii clinical isolates: isolation of highly pathogenic multidrug-resistant A. baumannii and experimental therapeutics with fourth-generation cephalosporin cefozopran

7 Nature-Inspired Drugs: Expanding Horizons of Contemporary Therapeutics

8 Comparative analysis of the pathogenicity between multidrug-resistant Acinetobacter baumannii clinical isolates: isolation of highly pathogenic multidrug-resistant A. baumannii and experimental therapeutics with fourth-generation cephalosporin cefozopran

9 Nanomaterials multifunctional behavior for enlighten cancer therapeutics.

10 Luminescent Iridium Complex-Peptide Hybrids (IPHs) for Therapeutics of Cancer: Design and Synthesis of IPHs for Detection of Cancer Cells and Induction of Their Necrosis-Type Cell Death

11 Correction to: Beyond HbA1c: Comparing glycemic variability and glycemic indices in predicting hypoglycemia in Type 1 and Type 2 diabetes (Diabetes Technology and Therapeutics (2018) 20:5 (353-362) DOI: 10.1089/dia.2017.0388)

12 In silico probing exercises, bioactive-conformational and dynamic simulations strategies for designing and promoting selective therapeutics against Helicobacter pylori strains.

13 Pharmacokinetics of oral therapeutics delivered by dendrimer-based carriers.

14 Competing Endogenous RNA and Coexpression Network Analysis for Identification of Potential Biomarkers and Therapeutics in association with Metastasis Risk and Progression of Prostate Cancer.

15 Efficient nanocarriers of siRNA therapeutics for cancer treatment.

16 Bacterial magnetosomes-based nanocarriers for co-delivery of cancer therapeutics in vitro

17 siRNA- and miRNA-based therapeutics for liver fibrosis.

18 Salivary glands as a potential gene transfer target for gene therapeutics of some monogenetic endocrine disorders

19 RNA therapeutics: Identification of novel targets leading to drug discovery.

20 A zebrafish drug screening platform boosts the discovery of novel therapeutics for spinal cord injury in mammals

21 Quantitative mechanistic modeling in support of pharmacological therapeutics development in immuno-oncology

22 Immuno-Oncology - The Translational Runway for Gene Therapy: Gene Therapeutics to Address Multiple Immune Targets

23 Immuno-engineering: The Next Frontier in Therapeutics Delivery

24 Neuro-immuno-endocrine considerations for cancer development and therapeutics

25 Tumor-targeted immuno-liposomes for delivery of therapeutics and diagnostics

26 Creation of an interdivisional facility. Preparation of immunotherapeutics, cell therapeutics and gene therapeutics

27 Endocrine exophthalmus and optic neuropathy. Results of immuno suppressive therapeutics

28 Practical applications of immunosuppressive therapeutics

29 Cyborg psychiatry to ensure agency and autonomy in mental disorders. A proposal for neuromodulation therapeutics.

30 Data-driven engineering of protein therapeutics

31 Engineering Microbial Living Therapeutics: The Synthetic Biology Toolbox.

32 Peptide nucleic acid (PNA) and its applications in chemical biology, diagnostics, and therapeutics.

33 Tailored therapeutics based on 1,2,3-1-triazoles: a mini review.

34 Telomerase Biology Associations offer Keys to Cancer and Aging Therapeutics.

35 Click Reactions in Chemistry of Triterpenes - Advances Towards Development of Potential Therapeutics.

36 Mouse Models of Thyroid Cancer: Bridging Pathogenesis and Novel Therapeutics.

37 Targeting the Versatile Wnt/β-Catenin Pathway in Cancer Biology and Therapeutics: From Concept to Actionable Strategy.

38 Small molecule PIKfyve inhibitors as cancer therapeutics: Translational promises and limitations.

39 Applications of alginate microspheres in therapeutics delivery and cell culture: Past, present and future.

40 Precision antimicrobial therapeutics: the path of least resistance?

41 ‘Questions concerning attention and Stiegler’s therapeutics’

42 Cystic fibrosis gene modifier SLC26A9 modulates airway response to CFTR-directed therapeutics.

43 Unleashing the full potential of Hsp90 inhibitors as cancer therapeutics through simultaneous inactivation of Hsp90, Grp94, and TRAP1.

44 An Automatable Hydrogel Culture Platform for Evaluating Efficacy of Antibody-based Therapeutics in Overcoming Chemoresistance.

45 Correction: Triple Reuptake Inhibitors as Potential Therapeutics for Depression and Other Disorders: Design Paradigm and Developmental Challenges" (Journal of Medicinal Chemistry (2018) 61:6 (2133-2165) DOI: 10.1021/acs.jmedchem.6b01827)

46 Perspective on the Therapeutics of Anti-Snake Venom

47 Small molecules as central nervous system therapeutics: old challenges, new directions, and a philosophic divide.

48 Anticonvulsant valproic acid and other short-chain fatty acids as novel anticancer therapeutics: Possibilities and challenges.

49 Targeting the Fanconi Anemia Pathway to Identify Tailored Anticancer Therapeutics

50 Laminin and Integrin in LAMA2-Related Congenital Muscular Dystrophy: From Disease to Therapeutics.

51 Machine intelligence in peptide therapeutics: A next-generation tool for rapid disease screening.

52 Type I Interferonopathies: from a Novel Concept to Targeted Therapeutics.

53 Targeting protein and peptide therapeutics to the heart via tannic acid modification.

54 CRISPR Diagnosis and Therapeutics with Single Base Pair Precision

55 Recruiting the 2-5A system for antisense therapeutics

56 Opportunities and challenges in developing Alzheimer disease therapeutics

57 CRISPR/Cas9 therapeutics: a cure for cancer and other genetic diseases

58 dietary flavonoids as therapeutics for preterm birth: luteolin and kaempferol suppress inflammation in human gestational tissues in vitro

59 response to: broadbent 2020, better the drug you know: commentary on “daughton 2020, natural experiment concept to accelerate the re-purposing of existing therapeutics for covid-19”

60 micrornas signatures, bioinformatics analysis of mirnas, mirna mimics and antagonists, and mirna therapeutics in osteosarcoma

61 rho gtpase regulators and effectors in autism spectrum disorders: animal models and insights for therapeutics

62 from molecular classification to targeted therapeutics: the changing face of systemic therapy in metastatic gastroesophageal cancer

63 therapeutic interchange of parenteral anticoagulants: challenges for pharmacy and therapeutics committees

64 terapêutica religiosa, o corpo e a saúde em yoga, ayurveda e tantra religious therapeutics, body and health in yoga, ayurveda, and tantra

65 erbb polymorphisms: insights and implications for response to targeted cancer therapeutics

66 developments and challenges for mab-based therapeutics

67 targeted delivery of sirna therapeutics to malignant tumors

68 clinics and therapeutics

69 implications of aneuploidy for stem cell biology and brain therapeutics

70 implications of micrornas in colorectal cancer development, diagnosis, prognosis and therapeutics

71 s-palmitoylation regulates ampa receptors trafficking and function: a novel insight into synaptic regulation and therapeutics

72 biomarkers in mood disorders research: developing new and improved therapeutics

73 voltage-dependent anion channel 1 as an emerging drug target for novel anti-cancer therapeutics

74 commentary: central-acting therapeutics alleviate respiratory weakness caused by heart failure–induced ventilatory overdrive

75 Erratum: Willis E. chiropractic in Australia (Journal of Manipulative and Physiol Therapeutics, January, 1991; 14:59-69)

76 ten years’ experience with the cyp2d6 activity score: a perspective on future investigations to improve clinical predictions for precision therapeutics

77 nanoparticle-based delivery of rnai therapeutics: progress and challenges

78 telomere and telomerase therapeutics in cancer

79 designing of some novel metallo antibiotics tuning biochemical behaviour towards therapeutics: synthesis, characterisation and pharmacological studies of metal complexes of cefixime

80 innovative therapeutics

81 cathepsin b is a new drug target for traumatic brain injury therapeutics: evidence for e64d as a promising lead drug candidate

82 emerging insights into barriers to effective brain tumor therapeutics

83 targeting pancreatic cancer cell plasticity: the latest in therapeutics

84 the advances of carbon nanotubes in cancer diagnostics and therapeutics

85 mechanistic systems modeling to improve understanding and prediction of cardiotoxicity caused by targeted cancer therapeutics

86 designing acellular injectable biomaterial therapeutics for treating myocardial infarction and peripheral artery disease

87 from mollusks to medicine: a venomics approach for the discovery and characterization of therapeutics from terebridae peptide toxins

88 antigen-based immune therapeutics for type 1 diabetes: magic bullets or ordinary blanks?

89 grand challenge for ion channels: an underexploited resource for therapeutics.

90 potential of known and short prokaryotic protein motifs as a basis for novel peptide-based antibacterial therapeutics: a computational survey.

91 the role of heparanase and sulfatases in the modification of heparan sulfate proteoglycans within the tumour microenvironment and opportunities for novel cancer therapeutics

92 editorial: microglial polarization in the pathogenesis and therapeutics of neurodegenerative diseases

93 unexplained abdominal pain as a driver for inappropriate therapeutics: an audit on the use of intravenous proton pump inhibitors

94 influenza a virus entry: implications in virulence and future therapeutics

95 new therapeutics in promoting and modulating mandibular growth in cases with mandibular hypoplasia

96 drug-resistant urothelial cancer cell lines display diverse sensitivity profiles to potential second-line therapeutics

97 glp-1 based therapeutics: simultaneously combating t2dm and obesity

98 stem cells applications in regenerative medicine and disease therapeutics

99 gold nanostructures as a platform for combinational therapy in future cancer therapeutics

100 Nursing therapeutics: Teaching student nurses care, compassion and empathy

101 Assessment: Transcranial Doppler ultrasonography: [RETIRED]: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology*

Keyword Connections

Journals

Research Groups

Bibliographies